Companies › Leadingtac Pharmaceutical (Shaoxing)
1 active drug program in 3 registered trials: 2 Phase 1, 1 Phase 2; Immunology; next expected readout Jan 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| LT-002-158 Tablets | – | Phase 2 | Atopic Dermatitis (AD); Hidradenitis Suppurativa (HS) | Jan 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT07895615 | LT-002-158 Tablets | Phase 2 | Atopic Dermatitis (AD) | Immunology | Jan 2028 |
| NCT06931990 | LT-002-158 Tablets | Phase 1 | Atopic Dermatitis (AD) | Immunology | Feb 2028 |
| NCT06932003 | LT-002-158 Tablets | Phase 1 | Hidradenitis Suppurativa (HS) | Immunology | Oct 2028 |
No annotated target.
–
Calixis Morphic Therapeutic, Inc. (A Wholly Owned Subsidiary of Eli Lilly and Company) Qifeng Zhang Topadur Pharma Agomab Spain S.L.U.
Pipelines of the same shape: areas, drug types, target families, stage and cash runway.
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.